Unicycive Therapeutics Earnings Estimate

By analyzing Unicycive Therapeutics' earnings estimates, investors can diagnose different trends across Unicycive Therapeutics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Unicycive Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options. Unicycive Therapeutics is projected to generate -0.14625 in earnings per share on the 31st of December 2024. Unicycive Therapeutics earnings estimates module stress-tests analyst consensus about projected Unicycive Therapeutics EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Many public companies, such as Unicycive Therapeutics, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Unicycive Therapeutics' earnings estimates, investors can diagnose different trends across Unicycive Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes. At this time, Unicycive Therapeutics' Gross Profit is fairly stable compared to the past year. Gross Profit Margin is likely to rise to 0.87 in 2024, whereas Pretax Profit Margin is likely to drop (47.51) in 2024. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Unicycive Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.